AHA today urged the Food and Drug Administration to take “any and all steps possible” to resolve worsening shortages of small-volume parenteral solutions that are fundamental to patient care in hospitals. “We are concerned that the shortages of widely-used and critical products are quickly becoming a crisis and looming threat to the public’s health,” wrote AHA Executive Vice President Tom Nickels. “Therefore, we call on the FDA to vigorously pursue strategies with the current manufacturers of these products and to seek out new suppliers in order to ameliorate the current shortage, as well as prevent such shortages from occurring in the future.” Current shortages of small-volume parenteral solutions include 50 and 100 milliliter injection bags of sodium chloride 0.9%, dextrose 5% and intravenous nutritional products.

Related News Articles

Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.